Sleep disorder

Azafaros to present data from PRONTO study in patients with GM1 and GM2 gangliosidoses at the 20th annual WORLDSymposium™

Retrieved on: 
Tuesday, January 23, 2024

As well as data from PRONTO, Azafaros will present details of its Phase 2 RAINBOW study, aimed at investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of nizubaglustat in patients with GM2 gangliosidosis or NPC.

Key Points: 
  • As well as data from PRONTO, Azafaros will present details of its Phase 2 RAINBOW study, aimed at investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of nizubaglustat in patients with GM2 gangliosidosis or NPC.
  • Title: A natural history study of late-infantile and juvenile GM1 and GM2 gangliosidoses (PRONTO) - patients’ and caregivers’ assessments.
  • Title: A natural history study of late-infantile and juvenile GM1 and GM2 gangliosidoses (PRONTO)- baseline clinical data.
  • Title: A natural history study of late-infantile and juvenile GM1 and GM2 gangliosidoses (PRONTO) - evaluation of different assessments.

In October 2023, COVID-19 No Longer in Top Five Telehealth Diagnoses Nationally or in Any Census Region

Retrieved on: 
Tuesday, January 9, 2024

NEW YORK, Jan. 9, 2024 /PRNewswire/ -- In October 2023, COVID-19 fell out of the top five telehealth diagnoses nationally and in the Midwest and Northeast, according to FAIR Health's Monthly Telehealth Regional Tracker. It remained absent from the top five telehealth diagnoses in the other two US census regions, the South and West, as it had in September. The data include claims for the privately insured population and Medicare Advantage but exclude Medicare Fee-for-Service and Medicaid.

Key Points: 
  • It remained absent from the top five telehealth diagnoses in the other two US census regions, the South and West, as it had in September.
  • Nationally, COVID-19 had been in fourth place in September, but in October hypertension supplanted it in that position.
  • The diagnosis of substance use disorders, which had been in fifth place nationally in September, was replaced by endocrine and metabolic disorders in October.
  • In October, diabetes mellitus rose from fifth place to fourth place nationally in the top five rankings of asynchronous telehealth diagnoses.

Human medicines European public assessment report (EPAR): Wakix, pitolisant, Date of authorisation: 31/03/2016, Revision: 16, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Wakix, pitolisant, Date of authorisation: 31/03/2016, Revision: 16, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Wakix, pitolisant, Date of authorisation: 31/03/2016, Revision: 16, Status: Authorised

Swiss Startup Aesyra Raised $3 Million in Seed Financing from Global Investors to Advance Innovations to Tackle Bruxism and Sleep Apnea

Retrieved on: 
Wednesday, December 13, 2023

Aesyra , a medical device company pioneering oral appliance technologies to improve sleep, today announced it has raised $3 million in seed financing.

Key Points: 
  • Aesyra , a medical device company pioneering oral appliance technologies to improve sleep, today announced it has raised $3 million in seed financing.
  • The new financing will support the development and commercialization of Aesyra’s AesyBite® line of products for accurate monitoring and treatment of sleep bruxism and sleep apnea.
  • Sleep bruxism is a sleep disorder often linked to sleep apnea, which affects nearly a billion people worldwide.
  • "This significant investment marks a pivotal moment for Aesyra,” said Marco Letizia, founder and CEO of Aesyra.

Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)

Retrieved on: 
Thursday, December 7, 2023

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and BIAL - Portela & Ca., S.A. (“BIAL”), today announced a licensing agreement where Amneal will have exclusive rights to market and distribute ONGENTYS® (opicapone) in the U.S. starting on December 18, 2023.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and BIAL - Portela & Ca., S.A. (“BIAL”), today announced a licensing agreement where Amneal will have exclusive rights to market and distribute ONGENTYS® (opicapone) in the U.S. starting on December 18, 2023.
  • Carbidopa/levodopa (CD/LD), which works to control the symptoms of PD, has been the gold-standard treatment for PD since the 1970s.
  • ONGENTYS® works by inhibiting the COMT enzyme – which breaks down LD – making more LD available to reach the brain, thereby reducing “Off” time.
  • The financial terms of the agreement were not disclosed, and any incremental expenses associated with this product are contemplated within Amneal’s guidance.

Sleep Reset Now Available for Health Savings and Flexible Spending Account Holders

Retrieved on: 
Tuesday, December 12, 2023

SAN FRANCISCO, Dec. 12, 2023 /PRNewswire/ -- Sleep Reset has announced that starting on December 11th, their clinically-proven sleep program is now Health Savings Account (HSA) and Flex Spending Account (FSA) eligible.

Key Points: 
  • SAN FRANCISCO, Dec. 12, 2023 /PRNewswire/ -- Sleep Reset has announced that starting on December 11th, their clinically-proven sleep program is now Health Savings Account (HSA) and Flex Spending Account (FSA) eligible.
  • "Our mission at Sleep Reset is to provide easy, immediate access to sleep care in order to improve quality of life for millions of people," says Yunha Kim, the Founder and CEO of Sleep Reset.
  • In a recent peer-reviewed study , sleep doctors found that Sleep Reset members experienced significant improvements in their sleep.
  • Following these scientific findings, a growing number of providers have been referring their patients with insomnia symptoms to Sleep Reset.

Sleep Reset Launches Employers Program to Combat Sleep Health Crisis in the Workplace

Retrieved on: 
Wednesday, December 6, 2023

SAN FRANCISCO, Dec. 6, 2023 /PRNewswire/ -- Sleep Reset , a clinically-proven sleep program, announced the launch of its Employers Program.

Key Points: 
  • SAN FRANCISCO, Dec. 6, 2023 /PRNewswire/ -- Sleep Reset , a clinically-proven sleep program, announced the launch of its Employers Program.
  • Sleep Reset's Employers Program offers an effective solution for employers to significantly decrease costs associated with mistakes and health issues worsened by poor sleep.
  • In a recent peer-reviewed study , sleep doctors found that Sleep Reset members increased their total sleep time by an average of 85 minutes.
  • "Our Employers Program is a strategic initiative designed to empower organizations to prioritize the sleep health of their teams.

Project Sleep Launches the Sleep Helpline™ to Provide Free and Personalized Support for People Facing Sleep Issues and Sleep Disorders

Retrieved on: 
Wednesday, December 6, 2023

LOS ANGELES, Dec. 6, 2023 /PRNewswire/ -- Project Sleep, a nonprofit dedicated to raising awareness of sleep health, sleep equity, and sleep disorders, is thrilled to announce the official launch of the Sleep Helpline™, a new, professionally-staffed national helpline providing timely and trusted resources to help individuals navigate sleep issues and sleep disorders at every step of the journey.

Key Points: 
  • "An estimated 50-70 million Americans live with a chronic sleep disorder, yet the majority are undiagnosed," said Julie Flygare , JD, President & CEO of Project Sleep.
  • "We know that the path to finding accurate sleep disorder diagnosis, treatment, and support is often long, lonely, and inefficient.
  • This is why the new Sleep Helpline will meet people where they are in moments of uncertainty, to provide free and personalized one-to-one support and resources."
  • Special thanks to Jazz Pharmaceuticals and Harmony Biosciences for generously providing sponsorship funding to support the development of Project Sleep's new Sleep Helpline to support millions of people facing sleep issues and sleep disorders.

New "Aging Backward, Growing Forward" Podcast Delves into Longevity, Healthspan & Optimal Performance with Eric Casaburi

Retrieved on: 
Monday, October 30, 2023

ORLANDO, Fla., Oct. 30, 2023 /PRNewswire/ -- Leading health and fitness entrepreneur Eric Casaburi, who has advanced the health and wellbeing of individuals everywhere through his fitness and anti-aging brand empires, announced today the introduction of Aging Backward, Growing Forward. The new podcast, which features dynamic monologues by Casaburi and interviews with prominent guests, challenges traditional medical practices and social media health trends while introducing audiences to freshly innovated and proven methods to help hack the human biochemistry and improve their individual performance and healthspans.

Key Points: 
  • "Today people have tools that allow them to take control of their own health and wellbeing.
  • As a serial entrepreneur in the fitness and longevity industries, I have had the opportunity to witness the successful health journeys of thousands.
  • From the personal trainer to your favorite superheroes to the field's leading physician for sleep and performance, the guest list is spectacular.
  • In a conversation with Casaburi, Saladino discusses the foundations of fitness and how to motivate someone toward their fitness goals.

HARMONY BIOSCIENCES SHOWCASES THE NEWEST PATIENTS AT THE HEART AND PROGRESS AT THE HEART AWARD RECIPIENTS

Retrieved on: 
Thursday, October 26, 2023

"With support from a previous Patients at the Heart award, we achieved the 'Strategic Communications for Awareness' project, which fortified and expanded our patient registry and outreach endeavors.

Key Points: 
  • "With support from a previous Patients at the Heart award, we achieved the 'Strategic Communications for Awareness' project, which fortified and expanded our patient registry and outreach endeavors.
  • Progress at the Heart provides funding support for novel initiatives addressing disparities, injustices, and inequities in rare neurological disease and sleep disorder communities.
  • The next call for Patients at the Heart and Progress at the Heart award nominations will be announced next year.
  • To learn more about Patients at the Heart, please visit: https://www.harmonybiosciences.com/funding-programs/patients-at-the-heart/ .